Clinical trial • Immunology|Infectious Disease|Respiratory
Regulatory T cells for Immune hyperactivation associated with COVID-19|Acute respiratory distress syndrome
Clinical trial of Regulatory T cells for Immune hyperactivation associated with COVID-19|Acute respiratory distress syndrome. 24 participants.
Overview
- Trial Therapeutic Area
- Immunology|Infectious Disease|Respiratory
- Trial Disease
- Immune hyperactivation associated with COVID-19|Acute respiratory distress syndrome
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 29-01-2025
- First CTIS Authorization Date
- 30-01-2025
Trial design
Clinical trial across 1 site in Spain.
- Target Sample Size
- 24
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Spain
- Earliest CTIS Part Ii Submission Date
- 27-01-2025
- Latest Decision Or Authorization Date
- 21-04-2026
- Processing Time Days
- 449
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Hospital General Universitario Gregorio Maranon
- Department Name
- Inmunology
- Principal Investigator Name
- Rafael Correa Rocha
- Principal Investigator Email
- rafael.correa@iisgm.com
- Contact Person Name
- Rafael Correa Rocha
- Contact Person Email
- rafael.correa@iisgm.com
- Number Of Participants
- 24
Sponsor
Primary sponsor
- Full Name
- Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Maranon
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- Regulatory T cells
- Active Substance
- Regulatory T cells
- Modality
- Cell therapy
Related trials
Other published trials that may interest you.
- THYTREG for Cardiac transplant rejection
- SODIUM THIOSULFATE for Peritoneal carcinomatosis|Peritoneal metastases
- ARBACLOFEN for Autism spectrum disorder
- Colchicine (also listed with opium standardized powdered and tiemonium methylsulphate in product record) for Chronic kidney disease (moderate) | Cardiovascular disease (secondary prevention)